30.10.2025, 17:00
Talk im Cube: CROs IN DIAGNOSTICS AND THERAPEUTICS DEVELOPMENT
We continue the Talks in the Cube with another expert discussion – the last event for 2025 focusses on Strategies to optimize the cooperation between the sponsor and Contract Research Organizations (C...
more ...
04.11.2025, 16:00
Kryo-Elektronenmikroskopie: Tiefgekühlte Proben ermöglichen das Verständnis biologischer Mechanismen
Vorlesungsreihe: Neue Wege in der Biomedizin: Aktuelle Forschungsthemen vom Campus Berlin-Buch. Für Lehrkräfte, Schülerinnen und Schüler sowie Interessierte.
more ...
05.11.2025, 14:00
Einladung zur Vorlesung: Neurobiologie - Forschung und neue Therapieansätze
Fortbildungsveranstaltung der Neurowissenschaftlichen Gesellschaft e.V. im Rahmen der Vorlesungsreihe: Neue Wege in der Biomedizin: Aktuelle Forschungsthemen vom Campus Berlin-Buch
more ...
T-knife Therapeutics is one of the most successful start-ups in the biotech scene. Founded in 2018 as a spin-off of the Max Delbrück Center for Molecular Medicine (MDC) with the support of Charité – Universitätsmedizin Berlin, its mission is to develop therapies that can combat cancer with the help of patients’ immune systems. Over the course of many years, the research team led by Professor Thomas Blankenstein has worked towards genetically modifying human T cells in such a way that their receptors can target and destroy specific tumor cells. Using this unique technology, the first T-cell receptor gene therapy in Germany is now being tested in a clinical trial.
An own prevention and fitness center for the Campus? Regular sports courses and health days on topics such as stress reduction or nutrition? And all of this is supported jointly by the institutions and companies on campus? Since 2016, there has been
Magnetic resonance imaging (MRI) is a method for diagnosing diseases and monitoring the course of therapy. It produces sectional images of the human body without using harmful radiation. Typically, the water molecules
Dr. Andreas Eckert is not directly involved in research to find cures for diseases, but he has dedicated his career to the life sciences. His objective is to invest in promising companies in the early phase of their development, which he does with
Dr. Ralf Krähmer never thought he would one day found a company in Berlin-Buch. Following his chemistry studies in Leipzig, Dr. Krähmer went to the U.S. for a research stay. From there he went to Switzerland and then on to Berlin, where he for the
The prospect that the first clinical trials will lead to the successful treatment of patients inspires and motivates the team of OMEICOS Therapeutics GmbH. All previous data suggest that the scientists and founders have for the first time found a
